Vincerx Pharma, Inc. Common Stock (VINC) - Net Assets
Based on the latest financial reports, Vincerx Pharma, Inc. Common Stock (VINC) has net assets worth $2.07 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.69 Million) and total liabilities ($2.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VINC financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.07 Million |
| % of Total Assets | 44.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | -95.28% |
| 10-Year Change | N/A |
| Growth Volatility | 62.29 |
Vincerx Pharma, Inc. Common Stock - Net Assets Trend (2019–2024)
This chart illustrates how Vincerx Pharma, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore Vincerx Pharma, Inc. Common Stock (VINC) total assets for the complete picture of this company's asset base.
Annual Net Assets for Vincerx Pharma, Inc. Common Stock (2019–2024)
The table below shows the annual net assets of Vincerx Pharma, Inc. Common Stock from 2019 to 2024. For live valuation and market cap data, see market value of Vincerx Pharma, Inc. Common Stock.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.72 Million | -75.73% |
| 2023-12-31 | $11.22 Million | -76.46% |
| 2022-12-31 | $47.67 Million | -52.48% |
| 2021-12-31 | $100.32 Million | +73.91% |
| 2020-12-31 | $57.69 Million | +134255.81% |
| 2019-12-31 | $-43.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vincerx Pharma, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18914100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.29% |
| Other Comprehensive Income | $119.00K | 4.37% |
| Other Components | $191.78 Million | 7040.49% |
| Total Equity | $2.72 Million | 100.00% |
Vincerx Pharma, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Vincerx Pharma, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CPPGroup Plc
LSE:CPP
|
$67.59K |
|
Empire Metals Limited
LSE:GEO
|
$68.09K |
|
Ondo InsurTech PLC
LSE:ONDO
|
$68.36K |
|
Quantum Blockchain Technologies Plc
LSE:QBT
|
$68.64K |
|
Crimson Tide plc
LSE:TIDE
|
$66.00K |
|
Dianomi PLC
LSE:DNM
|
$65.76K |
|
Westmount Energy Limited
LSE:WTE
|
$65.73K |
|
Aeorema Communications Plc
LSE:AEO
|
$65.64K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vincerx Pharma, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,222,000 to 2,724,000, a change of -8,498,000 (-75.7%).
- Net loss of 30,074,000 reduced equity.
- New share issuances of 17,874,000 increased equity.
- Other comprehensive income increased equity by 111,000.
- Other factors increased equity by 3,591,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.07 Million | -1104.04% |
| Share Issuances | $17.87 Million | +656.17% |
| Other Comprehensive Income | $111.00K | +4.07% |
| Other Changes | $3.59 Million | +131.83% |
| Total Change | $- | -75.73% |
Book Value vs Market Value Analysis
This analysis compares Vincerx Pharma, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.03 | $0.01 | x |
| 2020-12-31 | $17.82 | $0.01 | x |
| 2021-12-31 | $21.18 | $0.01 | x |
| 2022-12-31 | $8.22 | $0.01 | x |
| 2023-12-31 | $1.91 | $0.01 | x |
| 2024-12-31 | $0.52 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vincerx Pharma, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1104.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.94x
- Recent ROE (-1104.04%) is below the historical average (-280.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-49.60K |
| 2020 | -42.28% | 0.00% | 0.00x | 2.49x | $-13.27 Million |
| 2021 | -39.18% | 0.00% | 0.00x | 1.17x | $-49.34 Million |
| 2022 | -137.13% | 0.00% | 0.00x | 1.24x | $-70.13 Million |
| 2023 | -357.84% | 0.00% | 0.00x | 1.62x | $-41.28 Million |
| 2024 | -1104.04% | 0.00% | 0.00x | 2.94x | $-30.35 Million |
Industry Comparison
This section compares Vincerx Pharma, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vincerx Pharma, Inc. Common Stock (VINC) | $2.07 Million | 0.00% | 1.27x | $66.48K |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and prov… Read more